MARKET

GLUE

GLUE

Monte Rosa Therapeutics, Inc.
NASDAQ
18.24
+1.14
+6.64%
After Hours: 18.30 +0.07 +0.36% 18:50 06/12 EDT
OPEN
17.50
PREV CLOSE
17.10
HIGH
18.32
LOW
17.21
VOLUME
1.09M
TURNOVER
--
52 WEEK HIGH
25.77
52 WEEK LOW
4.120
MARKET CAP
1.54B
P/E (TTM)
-12.4633
1D
5D
1M
3M
1Y
5Y
1D
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential
Seeking Alpha · 2d ago
Monte Rosa Therapeutics held annual shareholder meeting
PUBT · 2d ago
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs
Seeking Alpha · 2d ago
Weekly Report: what happened at GLUE last week (0601-0605)?
Weekly Report · 5d ago
MONTE ROSA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/02 20:01
Monte Rosa Therapeutics CSO Sharon Townson disposes of common shares worth $119,220
PUBT · 06/01 20:07
Monte Rosa posts corporate deck spotlighting molecular glue degrader pipeline for immunology, inflammation and cancer targets
PUBT · 06/01 15:27
Weekly Report: what happened at GLUE last week (0525-0529)?
Weekly Report · 06/01 10:39
More
About GLUE
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Webull offers Monte Rosa Therapeutics Inc stock information, including NASDAQ: GLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GLUE stock methods without spending real money on the virtual paper trading platform.